Statements (101)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
Santen USA, Inc.
Ophthalmic division of Merck & Co. Novagali Pharma |
| gptkbp:acquisition |
Ophthalmology business of Merck & Co.
Santen's acquisition of the ophthalmic business of Merck & Co. |
| gptkbp:advertising |
gptkb:Ms._Yuki_Tanaka
|
| gptkbp:awards |
Innovation Award 2021
Top 100 Global Innovators 2020 Best Company Award 2020 Japan's Best Workplaces 2021 |
| gptkbp:ceo |
gptkb:Akihiro_Sato
Akihiro Kurokawa |
| gptkbp:clinical_trial |
Ongoing
Phase III trials Phase I trials Phase II trials Focus on patient outcomes Focus on drug efficacy Focus on safety profiles Phase I trials for retinal disease treatment Phase II trials for glaucoma treatment Phase III trials for dry eye treatment |
| gptkbp:collaboration |
gptkb:Osaka_University
gptkb:University_of_Tokyo gptkb:Kyoto_University |
| gptkbp:collaborations |
Academic institutions
Research organizations |
| gptkbp:community_engagement |
Patient support programs
Health education programs Local partnerships |
| gptkbp:conducts_research_on |
gptkb:Dr._Hiroshi_Takahashi
|
| gptkbp:employees |
Approximately 2,000
approximately 2,000 |
| gptkbp:financial_performance |
Consistent revenue growth
Strong profit margins Positive cash flow |
| gptkbp:founded |
1890
|
| gptkbp:future_plans |
Expansion into new markets
Development of new products Increased investment in R& D |
| gptkbp:global_presence |
Operations in North America
Operations in Europe Operations in Asia |
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Santen Pharmaceutical
|
| gptkbp:industry |
gptkb:pharmaceuticals
Pharmaceuticals |
| gptkbp:invention |
Numerous patents in ophthalmology
|
| gptkbp:investment |
Technology investments
R& D investments Market expansion investments |
| gptkbp:market |
Global
Asian market for pharmaceuticals European market for pharmaceuticals Japanese market for pharmaceuticals global market for ophthalmic products |
| gptkbp:operates_in |
gptkb:Europe
gptkb:Asia gptkb:Japan |
| gptkbp:partnership |
gptkb:Aerie_Pharmaceuticals
gptkb:Alcon gptkb:Bausch_+_Lomb gptkb:Novartis |
| gptkbp:product |
gptkb:Lumigan
gptkb:Xiidra Tafluprost Diquas Ikervis Santen's preservative-free eye drops Tears Again |
| gptkbp:products |
Ophthalmic pharmaceuticals
|
| gptkbp:research_areas |
Glaucoma
Allergic conjunctivitis Dry eye disease |
| gptkbp:research_focus |
gptkb:Ophthalmology
retinal diseases dry eye disease |
| gptkbp:research_institutes |
Santen Innovation Center
Santen Research Institute |
| gptkbp:revenue |
$1.2 billion (2020)
¥100 billion (2021) |
| gptkbp:specializes_in |
ophthalmology
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4536
|
| gptkbp:subsidiaries |
Santen SA
Santen Inc. |
| gptkbp:subsidiary |
Santen USA, Inc.
Santen Asia Santen Europe |
| gptkbp:sustainability_initiatives |
gptkb:Environmental_Protection_Agency
Environmental sustainability programs Social responsibility programs Governance practices Diversity and Inclusion programs Sustainable Development Goals (SDGs) alignment Corporate Social Responsibility programs |
| gptkbp:vision |
to contribute to the health of people worldwide through ophthalmology.
|
| gptkbp:website |
www.santen.com
|
| gptkbp:bfsParent |
gptkb:Daiichi_Sankyo_Company,_Limited
|
| gptkbp:bfsLayer |
7
|